Covance continues investment in the Asia Pacific region
Singapore laboratory expansion enhances Covance’s clinical service offerings.
In order to meet increasing demand for clinical testing services in the Asia Pacific region, Covance Inc. recently completed expansion of its laboratory facility in Singapore. This development is part of an investment plan for the Asia Pacific region and follows on from the company’s recent growth in services provided in China and Japan.
Corporate Vice President and Global General Manager of Central Laboratory Services at Covance, Jon Koch commented, “This expansion will help us better serve both our local and multinational customers’ R&D needs in key therapeutic areas like oncology and metabolic diseases while reflecting Covance’s continued commitment to the Asia Pacific region.”
The expanded laboratory is the largest of its kind in Singapore at 2700 m2 and will provide clinical testing to clients in Asia, South Korea, Taiwan, Hong Kong, the Philippines, Australia and India. This expansion will double Covance’s genomics impact in the country, also providing service offerings in chemistry, immunology, hematology, flow cytometry, anatomic pathology and microbiology.
Kevin Lai, Director of Biomedical Sciences Group from the Economic Development Board of Singapore explained how Covance’s investment will impact on the development of Singpaore’s position in the biomedical sciences, “Its investment is a strong vote of confidence in our efforts in developing Singapore as a leading biomedical sciences hub with strong capabilities to support translational and clinical research.”